Vibecotamab

Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/ (scFv-heavy-lambda) -h-CH2-CH3[1][2][3].

Product Specifications

CAS Number

[2138442-13-2]

Product Name Alternative

XmAb14045

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vibecotamab.html

Purity

99.34

Solubility

10 mM in DMSO

Smiles

[Vibecotamab]

Molecular Weight

(126.15 kDa)

References & Citations

[1]FarhadRavandiMBBS, et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study. Blood, Volume 136, Supplement 1, 5 November 2020, Pages 4-5|[2]Nicholas James Short et al., Meeting Abstract: 2023 ASCO Annual Meeting I, Journal of Clinical Oncology, Volume 41, Number 16|[3]Seung Y. Chu, et al., (2014) Immunotherapy with Long-Lived Anti-CD123 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia, Blood, Volume 124, Issue 21, Page 2316, ISSN 0006-4971.